Last reviewed · How we verify
silybin phosphatidylcholine
At a glance
| Generic name | silybin phosphatidylcholine |
|---|---|
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy (PHASE2)
- Effects of Silybin in Hypertensive Patients (PHASE4)
- Superior Silybin Bioavailability in Healthy Volunteers
- Study to Investigate the Absolute Bioavailability of Oral Sylibin (PHASE1)
- N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy (PHASE2)
- IdB 1016 Treatment for Hepatitis C Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: